MX2014002204A - Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma. - Google Patents

Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma.

Info

Publication number
MX2014002204A
MX2014002204A MX2014002204A MX2014002204A MX2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A
Authority
MX
Mexico
Prior art keywords
reducing
immunoglobulin composition
plasma
derived immunoglobulin
factor
Prior art date
Application number
MX2014002204A
Other languages
English (en)
Other versions
MX349005B (es
Inventor
Hans-Peter Schwarz
Wolfgang Teschner
Harald Arno Butterweck
Bernhard Koelbl
Lucia Hofbauer
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2014002204A publication Critical patent/MX2014002204A/es
Publication of MX349005B publication Critical patent/MX349005B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención describe métodos para reducir la actividad amidolítica y anti-complemento (ACA) de una composición de inmunoglobulina a través del uso de cromatografía de intercambio catiónico. En una modalidad específica, la invención provee métodos para reducir el contenido de Factor XI y/o Factor XIa y/o ACA en una composición de inmunoglobulina por recolección la porción principal de un eluato de intercambio catiónico. La presente invención también provee una composición de inmunoglobulina con niveles reducidos de actividad amidolítica, Factor XI y/o Factor XIa y/o ACA.
MX2014002204A 2011-08-26 2012-08-27 Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma. MX349005B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527974P 2011-08-26 2011-08-26
PCT/US2012/052567 WO2013033042A1 (en) 2011-08-26 2012-08-27 Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition

Publications (2)

Publication Number Publication Date
MX2014002204A true MX2014002204A (es) 2014-06-11
MX349005B MX349005B (es) 2017-07-06

Family

ID=46970397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002204A MX349005B (es) 2011-08-26 2012-08-27 Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma.

Country Status (20)

Country Link
US (1) US9403899B2 (es)
EP (1) EP2748193B1 (es)
JP (1) JP6165143B2 (es)
KR (1) KR101949553B1 (es)
CN (1) CN103874708B (es)
AR (1) AR087953A1 (es)
AU (1) AU2012300220C1 (es)
BR (1) BR112014004445B1 (es)
CA (1) CA2846599A1 (es)
CL (1) CL2014000480A1 (es)
CO (1) CO6920256A2 (es)
EA (1) EA030251B1 (es)
ES (1) ES2624485T3 (es)
HK (1) HK1199267A1 (es)
IL (1) IL231083B (es)
MX (1) MX349005B (es)
MY (1) MY165164A (es)
SG (1) SG11201400233TA (es)
TW (1) TWI610937B (es)
WO (1) WO2013033042A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP3118210B1 (en) * 2014-03-11 2019-11-13 Green Cross Holdings Corporation Method for purifying immunoglobulin
ES2785375T3 (es) 2014-03-11 2020-10-06 Green Cross Holdings Corp Procedimiento de purificación de inmunoglobulina
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
US11814442B2 (en) 2017-06-12 2023-11-14 Kamada Ltd. Immunoglobulin compositions and process for obtaining the same
TW202400621A (zh) * 2022-05-02 2024-01-01 日商武田藥品工業股份有限公司 經由超濾自血漿製備科恩池濃縮物之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
JPS5598117A (en) * 1979-01-17 1980-07-25 Chemo Sero Therapeut Res Inst Purification of gamma-globulin derivative
US4639513A (en) 1984-02-02 1987-01-27 Cuno Inc. Intravenously injectable immunoglobulin G (IGG) and method for producing same
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US4482483A (en) 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
EP0168506B2 (en) 1984-07-07 1998-01-07 Armour Pharma GmbH Process for preparing gamma globulin suitable for intravenous administration
DE3640513A1 (de) 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3641115A1 (de) 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
DE59309332D1 (de) 1993-12-27 1999-03-04 Rotkreuzstiftung Zentratrallab Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
TR200100303T2 (tr) * 1998-06-09 2001-06-21 Statens Serum Institut Damardan uygulanacak immünoglobülinler üretmek için yöntem ve başka immünoglobülin ürünleri.
US6281336B1 (en) * 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
CN102459331B (zh) * 2009-05-27 2015-01-28 巴克斯特国际公司 生产用于皮下使用的高度浓缩的免疫球蛋白制品的方法
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof

Also Published As

Publication number Publication date
KR20140062088A (ko) 2014-05-22
JP2014525417A (ja) 2014-09-29
MX349005B (es) 2017-07-06
TWI610937B (zh) 2018-01-11
EA201400273A1 (ru) 2014-08-29
MY165164A (en) 2018-02-28
CO6920256A2 (es) 2014-04-10
BR112014004445B1 (pt) 2022-11-22
AR087953A1 (es) 2014-04-30
KR101949553B1 (ko) 2019-02-18
CN103874708B (zh) 2018-07-10
AU2012300220A1 (en) 2013-05-02
CA2846599A1 (en) 2013-03-07
CN103874708A (zh) 2014-06-18
WO2013033042A1 (en) 2013-03-07
SG11201400233TA (en) 2014-08-28
EP2748193A1 (en) 2014-07-02
US9403899B2 (en) 2016-08-02
JP6165143B2 (ja) 2017-07-19
IL231083A0 (en) 2014-03-31
HK1199267A1 (en) 2015-06-26
AU2012300220B2 (en) 2015-09-10
CL2014000480A1 (es) 2014-10-03
TW201326192A (zh) 2013-07-01
BR112014004445A2 (pt) 2017-03-28
US20130058961A1 (en) 2013-03-07
AU2012300220C1 (en) 2016-11-10
ES2624485T3 (es) 2017-07-14
IL231083B (en) 2019-06-30
EP2748193B1 (en) 2017-02-01
EA030251B1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
MX349005B (es) Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma.
PH12014501108A1 (en) Anti-il-36r antibodies
IN2013MU02145A (es)
MX2018013128A (es) Molecula de union al antigeno para promover la perdia de antigeno a traves de fc gamma riib.
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX2019000046A (es) Anticuerpos anti-il-23.
NZ605400A (en) Chimeric clotting factors
MX2013010019A (es) Metodo para aislamiento de osteopontina utilizando alimentos concentrados.
MX342920B (es) Metodo para purificar polipeptidos o inmunoconjugados activos.
GB201407561D0 (en) Transaction processing system,method and program
MX2013007048A (es) Metodo para el tratamiento de textiles con endoglucanasa.
MX2014000531A (es) Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
PH12016500158A1 (en) Methods for controlling fucosylation levels in proteins
SG10201907901XA (en) Antibodies, uses & methods
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
WO2013187971A3 (en) Macrocycles
MX2016002274A (es) Procedimiento de purificacion para la hormona paratiroidea recombinante.
MX2014008417A (es) Un método para remover nitrogeno de amonio de agua con residuos orgánicos.
WO2013009686A3 (en) Methods for purification of arylsulfatase a
MX2013008103A (es) Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular.
UA74021U (ru) Способ лечения хронического вирусного гепатита с
SE1630303A1 (en) A new method for predicting uric acid composition in urinarystones using routine single energy computer tomography

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration